Long-term outcomes in patients with stage IV neuroblastoma

Mauricio A. Escobar, Jay L. Grosfeld, Robert L. Powell, Karen W. West, L. R. Scherer, Robert J. Fallon, Frederick J. Rescorla

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Aim of Study: Long-term outcome studies in survivors with stage IV neuroblastoma (NB) are sparse. This review evaluates late complications and long-term outcomes in stage IV NB survivors. Methods: A retrospective review of stage IV NB survivors was performed to analyze outcomes, including long-term morbidity, recurrence, and survival. Main Results: Of 153 patients with stage IV NB, 52 (34%) survived (male-female, 26:26). Age at diagnosis was 29.1 ± 31.7 months in survivors. Eighteen were 1 year or younger and 34 were older than 1 year compared with 10 nonsurvivors 1 year or younger and 91 older than 1 year (P = .0003, Fisher's Exact test). Primary tumor sites were adrenal (35), retroperitoneal (11), mediastinal (3), pelvic (2), and no primary with tumor metastases identified (1). Ten survivors had favorable and 16 had unfavorable histology compared with 1 favorable and 18 unfavorable in nonsurvivors (P = .01). Four survivors had MYCN amplification (≥10 copies) and 2 deletions of 1p and 11q. Sites of metastasis in survivors and nonsurvivors were similar. Treatment in survivors included surgery in 51 (75% [39/51] complete tumor resection [CTR]); chemotherapy, 50; radiation, 17; stem cell transplantation, 20; and bone marrow transplant, 1. In nonsurvivors, 13 (25%) of 53 (P ≪ .0001) had CTR, 18 stem cell transplantation, and 12 bone marrow transplant. Six patients had tumor recurrence but survived (mean, 9.3 ± 8.3 years; range, 6 months-24 years). Recurrence was local (1), distant (2), and both (3) and was treated by resection, chemotherapy, and radiation. The mean age of survivors was 12.4 ± 8.3 years (range, 2-34 years). In all stage IV cases, event-free survival was 30% and overall survival was 34%. Long-term complications occurred in 23 (44%) survivors, including endocrine disturbances (7), orthopedic (5), cataracts (2), adhesive bowel obstruction (2), hypertension (1), bronchiolitis (1), blindness (1), peripheral neuropathy (1), nonfunctioning kidney (1), cholelithiasis (1), and thyroid nodule (1). Conclusion: Only 34% of patients with stage IV NB survived despite aggressive multimodal therapy. Age of younger than 1 year, favorable pathology, CTR, and no recurrence were the only statistically significant factors that favored survival. Forty-four percent of survivors experienced late morbidity, and tumor recurred in 6 (11.5%) of 52. Patients should be monitored for tumor recurrence and long-term sequelae. New methods of treatment are required to achieve better outcomes.

Original languageEnglish (US)
Pages (from-to)377-381
Number of pages5
JournalJournal of Pediatric Surgery
Volume41
Issue number2
DOIs
StatePublished - Feb 1 2006

Fingerprint

Neuroblastoma
Survivors
Neoplasms
Recurrence
Stem Cell Transplantation
Survival
Bone Marrow
Radiation
Neoplasm Metastasis
Morbidity
Transplants
Drug Therapy
Bronchiolitis
Thyroid Nodule
Cholelithiasis
Peripheral Nervous System Diseases
Blindness
Adhesives
Cataract
Disease-Free Survival

Keywords

  • Complete tumor resection
  • MYCN
  • Neuroblastoma
  • Outcomes
  • Shimada classification
  • Stem cell transplantation

ASJC Scopus subject areas

  • Surgery

Cite this

Escobar, M. A., Grosfeld, J. L., Powell, R. L., West, K. W., Scherer, L. R., Fallon, R. J., & Rescorla, F. J. (2006). Long-term outcomes in patients with stage IV neuroblastoma. Journal of Pediatric Surgery, 41(2), 377-381. https://doi.org/10.1016/j.jpedsurg.2005.11.032

Long-term outcomes in patients with stage IV neuroblastoma. / Escobar, Mauricio A.; Grosfeld, Jay L.; Powell, Robert L.; West, Karen W.; Scherer, L. R.; Fallon, Robert J.; Rescorla, Frederick J.

In: Journal of Pediatric Surgery, Vol. 41, No. 2, 01.02.2006, p. 377-381.

Research output: Contribution to journalArticle

Escobar, MA, Grosfeld, JL, Powell, RL, West, KW, Scherer, LR, Fallon, RJ & Rescorla, FJ 2006, 'Long-term outcomes in patients with stage IV neuroblastoma', Journal of Pediatric Surgery, vol. 41, no. 2, pp. 377-381. https://doi.org/10.1016/j.jpedsurg.2005.11.032
Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR, Fallon RJ et al. Long-term outcomes in patients with stage IV neuroblastoma. Journal of Pediatric Surgery. 2006 Feb 1;41(2):377-381. https://doi.org/10.1016/j.jpedsurg.2005.11.032
Escobar, Mauricio A. ; Grosfeld, Jay L. ; Powell, Robert L. ; West, Karen W. ; Scherer, L. R. ; Fallon, Robert J. ; Rescorla, Frederick J. / Long-term outcomes in patients with stage IV neuroblastoma. In: Journal of Pediatric Surgery. 2006 ; Vol. 41, No. 2. pp. 377-381.
@article{f771ecefb0c44382b144984e204f28dd,
title = "Long-term outcomes in patients with stage IV neuroblastoma",
abstract = "Aim of Study: Long-term outcome studies in survivors with stage IV neuroblastoma (NB) are sparse. This review evaluates late complications and long-term outcomes in stage IV NB survivors. Methods: A retrospective review of stage IV NB survivors was performed to analyze outcomes, including long-term morbidity, recurrence, and survival. Main Results: Of 153 patients with stage IV NB, 52 (34{\%}) survived (male-female, 26:26). Age at diagnosis was 29.1 ± 31.7 months in survivors. Eighteen were 1 year or younger and 34 were older than 1 year compared with 10 nonsurvivors 1 year or younger and 91 older than 1 year (P = .0003, Fisher's Exact test). Primary tumor sites were adrenal (35), retroperitoneal (11), mediastinal (3), pelvic (2), and no primary with tumor metastases identified (1). Ten survivors had favorable and 16 had unfavorable histology compared with 1 favorable and 18 unfavorable in nonsurvivors (P = .01). Four survivors had MYCN amplification (≥10 copies) and 2 deletions of 1p and 11q. Sites of metastasis in survivors and nonsurvivors were similar. Treatment in survivors included surgery in 51 (75{\%} [39/51] complete tumor resection [CTR]); chemotherapy, 50; radiation, 17; stem cell transplantation, 20; and bone marrow transplant, 1. In nonsurvivors, 13 (25{\%}) of 53 (P ≪ .0001) had CTR, 18 stem cell transplantation, and 12 bone marrow transplant. Six patients had tumor recurrence but survived (mean, 9.3 ± 8.3 years; range, 6 months-24 years). Recurrence was local (1), distant (2), and both (3) and was treated by resection, chemotherapy, and radiation. The mean age of survivors was 12.4 ± 8.3 years (range, 2-34 years). In all stage IV cases, event-free survival was 30{\%} and overall survival was 34{\%}. Long-term complications occurred in 23 (44{\%}) survivors, including endocrine disturbances (7), orthopedic (5), cataracts (2), adhesive bowel obstruction (2), hypertension (1), bronchiolitis (1), blindness (1), peripheral neuropathy (1), nonfunctioning kidney (1), cholelithiasis (1), and thyroid nodule (1). Conclusion: Only 34{\%} of patients with stage IV NB survived despite aggressive multimodal therapy. Age of younger than 1 year, favorable pathology, CTR, and no recurrence were the only statistically significant factors that favored survival. Forty-four percent of survivors experienced late morbidity, and tumor recurred in 6 (11.5{\%}) of 52. Patients should be monitored for tumor recurrence and long-term sequelae. New methods of treatment are required to achieve better outcomes.",
keywords = "Complete tumor resection, MYCN, Neuroblastoma, Outcomes, Shimada classification, Stem cell transplantation",
author = "Escobar, {Mauricio A.} and Grosfeld, {Jay L.} and Powell, {Robert L.} and West, {Karen W.} and Scherer, {L. R.} and Fallon, {Robert J.} and Rescorla, {Frederick J.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1016/j.jpedsurg.2005.11.032",
language = "English (US)",
volume = "41",
pages = "377--381",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Long-term outcomes in patients with stage IV neuroblastoma

AU - Escobar, Mauricio A.

AU - Grosfeld, Jay L.

AU - Powell, Robert L.

AU - West, Karen W.

AU - Scherer, L. R.

AU - Fallon, Robert J.

AU - Rescorla, Frederick J.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Aim of Study: Long-term outcome studies in survivors with stage IV neuroblastoma (NB) are sparse. This review evaluates late complications and long-term outcomes in stage IV NB survivors. Methods: A retrospective review of stage IV NB survivors was performed to analyze outcomes, including long-term morbidity, recurrence, and survival. Main Results: Of 153 patients with stage IV NB, 52 (34%) survived (male-female, 26:26). Age at diagnosis was 29.1 ± 31.7 months in survivors. Eighteen were 1 year or younger and 34 were older than 1 year compared with 10 nonsurvivors 1 year or younger and 91 older than 1 year (P = .0003, Fisher's Exact test). Primary tumor sites were adrenal (35), retroperitoneal (11), mediastinal (3), pelvic (2), and no primary with tumor metastases identified (1). Ten survivors had favorable and 16 had unfavorable histology compared with 1 favorable and 18 unfavorable in nonsurvivors (P = .01). Four survivors had MYCN amplification (≥10 copies) and 2 deletions of 1p and 11q. Sites of metastasis in survivors and nonsurvivors were similar. Treatment in survivors included surgery in 51 (75% [39/51] complete tumor resection [CTR]); chemotherapy, 50; radiation, 17; stem cell transplantation, 20; and bone marrow transplant, 1. In nonsurvivors, 13 (25%) of 53 (P ≪ .0001) had CTR, 18 stem cell transplantation, and 12 bone marrow transplant. Six patients had tumor recurrence but survived (mean, 9.3 ± 8.3 years; range, 6 months-24 years). Recurrence was local (1), distant (2), and both (3) and was treated by resection, chemotherapy, and radiation. The mean age of survivors was 12.4 ± 8.3 years (range, 2-34 years). In all stage IV cases, event-free survival was 30% and overall survival was 34%. Long-term complications occurred in 23 (44%) survivors, including endocrine disturbances (7), orthopedic (5), cataracts (2), adhesive bowel obstruction (2), hypertension (1), bronchiolitis (1), blindness (1), peripheral neuropathy (1), nonfunctioning kidney (1), cholelithiasis (1), and thyroid nodule (1). Conclusion: Only 34% of patients with stage IV NB survived despite aggressive multimodal therapy. Age of younger than 1 year, favorable pathology, CTR, and no recurrence were the only statistically significant factors that favored survival. Forty-four percent of survivors experienced late morbidity, and tumor recurred in 6 (11.5%) of 52. Patients should be monitored for tumor recurrence and long-term sequelae. New methods of treatment are required to achieve better outcomes.

AB - Aim of Study: Long-term outcome studies in survivors with stage IV neuroblastoma (NB) are sparse. This review evaluates late complications and long-term outcomes in stage IV NB survivors. Methods: A retrospective review of stage IV NB survivors was performed to analyze outcomes, including long-term morbidity, recurrence, and survival. Main Results: Of 153 patients with stage IV NB, 52 (34%) survived (male-female, 26:26). Age at diagnosis was 29.1 ± 31.7 months in survivors. Eighteen were 1 year or younger and 34 were older than 1 year compared with 10 nonsurvivors 1 year or younger and 91 older than 1 year (P = .0003, Fisher's Exact test). Primary tumor sites were adrenal (35), retroperitoneal (11), mediastinal (3), pelvic (2), and no primary with tumor metastases identified (1). Ten survivors had favorable and 16 had unfavorable histology compared with 1 favorable and 18 unfavorable in nonsurvivors (P = .01). Four survivors had MYCN amplification (≥10 copies) and 2 deletions of 1p and 11q. Sites of metastasis in survivors and nonsurvivors were similar. Treatment in survivors included surgery in 51 (75% [39/51] complete tumor resection [CTR]); chemotherapy, 50; radiation, 17; stem cell transplantation, 20; and bone marrow transplant, 1. In nonsurvivors, 13 (25%) of 53 (P ≪ .0001) had CTR, 18 stem cell transplantation, and 12 bone marrow transplant. Six patients had tumor recurrence but survived (mean, 9.3 ± 8.3 years; range, 6 months-24 years). Recurrence was local (1), distant (2), and both (3) and was treated by resection, chemotherapy, and radiation. The mean age of survivors was 12.4 ± 8.3 years (range, 2-34 years). In all stage IV cases, event-free survival was 30% and overall survival was 34%. Long-term complications occurred in 23 (44%) survivors, including endocrine disturbances (7), orthopedic (5), cataracts (2), adhesive bowel obstruction (2), hypertension (1), bronchiolitis (1), blindness (1), peripheral neuropathy (1), nonfunctioning kidney (1), cholelithiasis (1), and thyroid nodule (1). Conclusion: Only 34% of patients with stage IV NB survived despite aggressive multimodal therapy. Age of younger than 1 year, favorable pathology, CTR, and no recurrence were the only statistically significant factors that favored survival. Forty-four percent of survivors experienced late morbidity, and tumor recurred in 6 (11.5%) of 52. Patients should be monitored for tumor recurrence and long-term sequelae. New methods of treatment are required to achieve better outcomes.

KW - Complete tumor resection

KW - MYCN

KW - Neuroblastoma

KW - Outcomes

KW - Shimada classification

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=32544459936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544459936&partnerID=8YFLogxK

U2 - 10.1016/j.jpedsurg.2005.11.032

DO - 10.1016/j.jpedsurg.2005.11.032

M3 - Article

C2 - 16481255

AN - SCOPUS:32544459936

VL - 41

SP - 377

EP - 381

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 2

ER -